Thermo Fisher Scientific is increasing their product portfolio in diagnostics in an aim to help the complete qPCR assay development and testing phase.

Following the Covid 19 pandemic, a new IVD framework from Thermo Fisher Scientific will empower assay developers and clinical testing labs to extend the list of tests they currently offer and improve IVD testing abilities.

“a new IVD framework from Thermo Fisher Scientific will empower assay developers and clinical testing labs“

The new product (the Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System) is a small device that can change from development to validation to achieve the highest possible level of output. The program of the product has pre-set settings to minimise the chance of problems occurring via human error as well as increasing efficiency. The device is specifically made so it can be started and used very quickly by lab technicians without the requirement for extra, professional training. The apparatus also features a range of other aspects including touchscreen controls, face recognition and smart tech support.

The FDA in the United States has labelled the product as a class II medical device.

Vice president and general manager of qPCR at Thermo Fisher, Santhosh Nair, said that "qPCR is an essential tool for clinical testing laboratories, and we have seen its importance for monitoring and managing the pandemic. We are continuing to expand our IVD portfolio to support our customers in this space. The QuantStudio 7 Pro Dx Real-Time PCR System can be used to develop new assays and then validate and run high-volume clinical diagnostic tests."